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Abstract  26 
In autosomal dominant polycystic kidney disease (ADPKD) activation of the renin-27 
angiotensin aldosterone system (RAAS) may contribute to hypertension and disease 28 
progression. Although previous studies focused on circulating RAAS-components, 29 
preliminary evidence suggests APDKD may increase urinary RAAS-components. Therefore, 30 
our aim was to analyze circulating and urinary RAAS-components in ADPKD. We cross-31 
sectionally compared 60 patients with ADPKD to 57 patients with non-ADPKD chronic 32 
kidney disease (CKD). The two groups were matched by gender, estimated glomerular 33 
filtration rate (eGFR), blood pressure, and RAAS-inhibitor use. Despite similar plasma levels 34 
of angiotensinogen and renin, urinary angiotensinogen and renin excretion were 5- to 6-fold 35 
higher in ADPKD (P<0.001). These differences persisted when adjusting for group 36 
differences, and were present regardless of RAAS-inhibitor use. In multivariable analyses, 37 
ADPKD, albuminuria, and the respective plasma concentrations were independent predictors 38 
for urinary angiotensinogen and renin excretion. In ADPKD, both plasma and urinary renin 39 
correlated negatively with eGFR. Total kidney volume correlated with plasma renin and 40 
albuminuria, but not with urinary renin or angiotensinogen excretions. Albuminuria 41 
correlated positively with urinary angiotensinogen and renin excretions in ADPKD and  42 
CKD. In three ADPKD patients who underwent nephrectomy, the concentrations of albumin 43 
and angiotensinogen were highest in plasma followed by cyst fluid and urine; urinary renin 44 
concentrations were higher than cyst fluid. In conclusion, this study shows that, despite 45 
similar circulating RAAS-component levels, higher urinary excretions of angiotensinogen 46 
and renin are a unique feature of ADPKD. Future studies should address the underlying 47 







Introduction  51 
Hypertension develops early in autosomal dominant polycystic kidney disease (ADPKD), 52 
usually occurring before a reduction in glomerular filtration rate (GFR) with an average age 53 
of onset of 30 years (5, 9). Increased activity of the renin-angiotensin-aldosterone system 54 
(RAAS) has been implicated in the pathogenesis of hypertension in ADPKD. One hypothesis 55 
is that cyst expansion results in areas of local renal ischemia which increases renin release (3, 56 
5). In addition, renin has also been suggested to be produced by the epithelial cells lining the 57 
cysts and active renin can be found within the cyst fluid (12, 36). However, measurement of 58 
plasma renin and aldosterone in patients with ADPKD yielded equivocal results (Table 1). 59 
Several studies found that plasma renin and aldosterone concentrations were not higher in 60 
hypertensive ADPKD patients when compared to controls, even during specific interventions 61 
(low or high sodium diet, ACE-inhibition, angiotensin II infusion) (1, 7, 21, 29, 37, 40). 62 
Different control groups were used for these studies, including normotensive ADPKD 63 
patients, normotensive siblings without ADPKD, patients with essential hypertension, or 64 
healthy volunteers (Table 1). The observation that plasma renin activity was not consistently 65 
higher in hypertensive ADPKD patients is notable, because this is contrary to what would be 66 
expected if cysts caused local renal ischemia (3, 5). Therefore, to further address the role of 67 
the RAAS in ADPKD, it may be informative to analyze RAAS-components in urine, as 68 
urinary angiotensinogen and renin have previously been used as markers of the intra-renal 69 
renin-angiotensin system (32). Emerging data suggest that filtered or locally produced 70 
RAAS-components may activate this intrarenal renin-angiotensin system and thereby 71 
contribute to hypertension (11). Two recent studies reported higher urinary angiotensinogen 72 
concentrations in hypertensive ADPKD patients (15, 25). However, despite its postulated 73 
central role in the pathogenesis of hypertension, urinary renin has never been measured in 74 





standardized assays, because commercial assays may produce  10-fold higher results (31). 76 
Therefore, here, we measured urinary renin in patients with ADPKD using a validated renin 77 
immunoradiometric assay and an in-house enzyme kinetic assay. In addition, we also 78 
measured multiple other RAAS-components in plasma and urine, including plasma renin and 79 
aldosterone, and urine angiotensinogen, prorenin, and aldosterone. As a comparator, and for 80 
the first time, we used matched patients with non-ADPKD chronic kidney disease (CKD) to 81 









Materials and Methods 87 
Patients 88 
Patients with ADPKD were recruited from one of the centers (Erasmus Medical Center, 89 
Rotterdam, The Netherlands) participating in a national ADPKD consortium (DIPAK study, 90 
with inclusion criteria CKD stage 3 at entry into the study and age ≤ 60 years) (23). Patients 91 
were matched to non-ADPKD CKD patients (referred to hereafter as ‘CKD’) from the 92 
PREVEND cohort (University Medical Center Groningen) (18). The Medical Ethics 93 
Committees of the Erasmus Medical Center and University Medical Center Groningen 94 
approved the studies (MEC-2012-313 and METC-90/01/022). Patients with ADPKD and 95 
CKD were individually matched for gender, eGFR (using the Modification of Diet in Renal 96 
Disease equation (19)), use of RAAS-inhibitors (defined as the use of angiotensin-converting 97 
enzyme inhibitors or angiotensin receptor blockers) and blood pressure (difference in systolic 98 
blood pressure ≤ 5 mmHg). Patients with a history of diabetes mellitus, or those using insulin 99 
or oral glucose lowering drugs were excluded, because diabetes mellitus may activate the 100 
intrarenal renin-angiotensin system (38). From three ADPKD patients who underwent 101 
elective nephrectomy (not part of the DIPAK cohort), we collected plasma, cyst fluid, and 102 
urine samples. For this part of the study, a separate approval from the Medical Ethics 103 
Committee of the University Medical Center Groningen was obtained (METC 2014.396). 104 
 105 
Data Collection 106 
Detailed description of data collection for both the DIPAK and PREVEND studies has been 107 
described elsewhere (18, 23). Briefly, participants of both studies collected 24-hour urine and 108 
visited the outpatient clinic for blood sampling and blood pressure measurements using an 109 
automatic oscillometric device. Hypertension was defined as a blood pressure > 140/90 110 





at 4°C during collection. Upon arrival in the university medical center, blood and urine 112 
samples were immediately stored at -80°C until further use. We have previously shown that 113 
in 24-hour urine, prorenin is not converted into renin prior to freezing (38). To determine 114 
adequate 24-hour urine collection, we calculated the expected 99% quantile of creatinine 115 
excretion based on previously defined criteria (10). Patients who exceeded the expected range 116 
were excluded (8 patients with ADPKD and 1 patient with CKD). ADPKD patients 117 
underwent magnetic resonance imaging to determine total kidney volume (23). The World 118 
Health Organization defined daily dose (DDD) was used to calculate daily RAAS-inhibitor 119 
use. 120 
 121 
Measurements  122 
Plasma and urine samples from the DIPAK and PREVEND cohorts were measured 123 
simultaneously. Renin in plasma was measured with a commercially available 124 
immunoradiometric kit (Renin III; Cisbio, Gif-sur-Yvette, France), making use of an active 125 
site-directed radiolabeled antibody (4). Total plasma renin was determined simultaneously 126 
using the same kit after the induction of a conformational change in the prorenin molecule 127 
with aliskiren (10 μmol/l for 48 hours at 4C), which enabled its recognition by the active 128 
site-directed radiolabeled antibodies applied in the Cisbio kit (2). The detection limit of this 129 
assay is 1 pg/ml with intra- and inter-assay coefficients of variation (CVs) of 2.4% and 7.2%. 130 
Urinary renin and urinary total renin (after prorenin activation with trypsin) were measured 131 
with an in-house enzyme kinetic assay (EKA) (16). This measurement involves the 132 
incubation of the urine sample with excess sheep angiotensinogen and angiotensinase 133 
inhibitors and the subsequent detection of the generated Ang I by radioimmunoassay. The 134 
detection limit of the EKA is 0.05 ng Ang I/ml per hour with intra- and inter-assay CVs of 135 





the fact that 1 ng Ang I/ml per hour corresponds with 2.6 pg human renin/ml (16). Prorenin 137 
was determined by subtraction of renin from total renin. Angiotensinogen in plasma and 138 
urine was measured as the maximum quantity of Ang I that was generated during incubation 139 
with excess recombinant renin (6). The detection limit of this assay is 0.50 pmol/ml with 140 
intra- and inter-assay CVs of 4 and 10%. Aldosterone was measured by solid-phase 141 
radioimmunoassay (Diagnostic Products Corporation, Los Angeles, California, USA), with a 142 
detection limit of 25 pg/ml with intra- and inter-assay CVs of 3.3 and 8.4% (14). 143 
 144 
Statistical Analyses  145 
Results are expressed as mean and standard deviation or median and range, as appropriate. 146 
Data were logarithmically transformed before analysis in case of non-normal distribution. 147 
Levels that were below the detection limit were considered to be half the detection limit to 148 
allow for statistical analysis (8). Analysis of variance (ANOVA) was used for group 149 
comparison (using log-transformed data as appropriate). Further analysis was performed 150 
using analysis of covariance (ANCOVA) to adjust for covariates. To analyze which 151 
parameters independently predicted urinary angiotensinogen or renin excretion, we 152 
performed multivariable linear regression. Finally, the Pearson correlation coefficient was 153 
analyzed for selected variables. A P-value < 0.05 was considered statistically significant. 154 
Statistical analyses were performed with SPSS (version 21, IBM).  155 






ADPKD Increases Urinary Angiotensinogen and Renin Excretion 158 
Table 2 shows the baseline characteristics and RAAS-component measurements for the 159 
ADPKD and CKD groups. Patients with ADPKD were younger (47 vs. 68 years), taller (175 160 
vs. 169 cm), and used more RAAS-inhibitors. While plasma levels of angiotensinogen, renin, 161 
and aldosterone were similar between the two groups, 24-hour urine volume, and urinary 162 
albumin, angiotensinogen, renin, and aldosterone excretions were significantly higher in 163 
patients with ADPKD (P < 0.05 for all). Similarly, when expressed as ratio with creatinine, 164 
urinary angiotensinogen and renin were also significantly higher in ADPKD (urinary 165 
angiotensinogen 14.6 vs. 3.3 pmol/mol creatinine, urinary renin 204 vs. 44 pg/mol creatinine, 166 
p < 0.01 for both). Because of the group differences in age, height, DDD, and albuminuria, 167 
we also performed a second analysis adjusting for these factors (Table 2). This analysis 168 
showed that urinary angiotensinogen and renin excretion were still significantly higher in 169 
ADPKD than CKD (P < 0.001 for both). In addition, a subanalysis was performed in patients 170 
(n = 17 vs. 11) with similar age, gender, height and a similar degree albuminuria , which also 171 
showed that urinary angiotensinogen (286.2 vs. 38.7 pmol/day) and renin (1874 vs. 398.6 172 
pg/day) excretions were significantly higher in ADPKD compared to CKD (P < 0.05 for 173 
both). 174 
 175 
Effects of RAAS-Inhibitors 176 
Because the use of RAAS-inhibitors increases plasma renin, this may also increase urinary 177 
renin. Therefore, we also report the plasma and urinary RAAS-components in patients with 178 
and without RAAS-inhibitor use (Figure 1). Plasma renin was indeed significantly higher in 179 
both ADPKD and CKD patients using RAAS-inhibitors. In patients without RAAS-180 





differences in plasma renin, urinary renin excretion was consistently higher in the patients 182 
with ADPKD than in the patients with CKD regardless of RAAS-inhibitor use (Figure 1). 183 
Urinary angiotensinogen excretion was significantly higher only in patients with ADPKD and 184 
RAAS-inhibitor use, but this may be a power issue, as few patients were without RAAS-185 
inhibitors. 186 
 187 
Predictors of Urinary Angiotensinogen and Renin Excretion 188 
Two multivariable linear regression analyses were performed to analyze which factors 189 
independently predict urinary angiotensinogen or urinary renin excretion (Table 3). In the 190 
model we included the presence of ADPKD, eGFR, age, DDD, plasma concentrations of 191 
angiotensinogen and renin, and urinary sodium and albumin excretion. For urinary 192 
angiotensinogen excretion, ADPKD, eGFR, plasma angiotensinogen, and albuminuria were 193 
identified as independent predictors. For urinary renin excretion, ADPKD, plasma renin, and 194 
albuminuria were identified as independent predictors. When the analyses were restricted to 195 
patients with ADPKD, only albuminuria predicted urinary angiotensinogen excretion, and 196 
only plasma renin predicted urinary renin excretion (data not shown).  197 
 198 
Correlations with Total Kidney Volume and Kidney Function 199 
Within the ADPKD group, we analyzed whether circulating or urinary RAAS-components 200 
correlated with total kidney volume and kidney function (eGFR). A higher total kidney 201 
volume correlated with higher plasma renin, and more albuminuria, but not with urinary 202 
angiotensinogen or renin excretion (Figure 2A). Both higher plasma renin and higher urinary 203 
renin excretion correlated with lower eGFR (Figure 2B). To analyze the possible mechanism 204 
of urinary angiotensinogen and renin excretion, we analyzed in the ADPKD and CKD groups 205 





patients with ADPKD and CKD, a higher degree of albuminuria correlated with higher 207 
urinary angiotensinogen or renin excretion, although the strength of this correlation was 208 
modest (Figure 2C). For urinary renin excretion, this correlation was of borderline 209 
significance in patients with ADPKD (P = 0.06). 210 
 211 
Comparison of Concentrations in Plasma, Cyst Fluid, and Urine 212 
In three patients with ADPKD who underwent nephrectomy, we measured albumin, 213 
angiotensinogen, prorenin, and renin in plasma, cyst fluid (average concentration of five 214 
cysts) and urine. For all four parameters, the concentrations were highest in plasma followed 215 
by cyst fluid and urine (Figure 3). Of interest, urinary concentrations were lower than cyst 216 
concentrations except for renin. Urinary prorenin concentrations were close to or below the 217 
detection limit.  218 






This study reveals a unique feature of patients with ADPKD, namely a consistently higher 221 
urinary excretion of angiotensinogen and renin compared to patients with CKD. Urinary 222 
angiotensinogen and renin excretions were 5- to 6-fold higher in patients with ADPKD than 223 
in patients with CKD, who were matched by eGFR, blood pressure, and RAAS-inhibitor use 224 
(Table 2). ADPKD remained a significant predictor for urinary angiotensinogen and renin 225 
excretion in adjusted and in multivariable analyses (Tables 2 and 3), and regardless of 226 
RAAS-inhibitor use (Figure 1). Recent studies found higher urinary angiotensinogen to 227 
creatinine ratios in normotensive ADPKD patients compared to healthy controls (17), or 228 
higher levels within ADPKD patients in the presence of hypertension (15) or reduced kidney 229 
function (25). The magnitude of the urinary angiotensinogen levels reported in these previous 230 
studies are comparable to our data. Our study is the first to analyze urinary renin and to use 231 
patients with CKD as control group (Table 1). Although our cross-sectional study cannot 232 
give definitive answers, our data give directions on the possible mechanisms and potential 233 
clinical implications of the increased urinary excretions.    234 
 235 
In principle, urinary angiotensinogen and renin excretion can increase in ADPKD because of 236 
(1) damage to the glomerular filtration barrier, (2) reduced proximal tubular reabsorption, (3) 237 
enhanced tubular secretion by intact nephrons, (4) differences in degradation, or (5) ectopic 238 
production by cyst-lining epithelial cells.  239 
 240 
When evaluating the first two possibilities, it is important to correct for differences in the 241 
plasma levels. Although the correlation between total kidney volume and plasma renin in 242 
ADPKD patients indeed suggests that renal ischemia by cysts can increase plasma renin 243 





concentrations than patients with CKD (Table 2). In fact, patients with ADPKD without 245 
RAAS-inhibitors had significantly lower plasma renin concentrations than patients with CKD 246 
(Figure 1). Thus, the higher urinary excretions of angiotensinogen and renin in ADPKD are 247 
not simply the consequence of elevated plasma RAAS concentrations exposed to the same 248 
degree of filtration and reabsorption as in CKD patients. In addition, increase of cysts (i.e. 249 
total kidney volume) did not correlate with increased excretion of urinary angiotensinogen or 250 
renin. Next, it is important to emphasize that ADPKD is a primarily a tubular disorder that is 251 
less likely to damage the glomerular filtration barrier (24). Indeed, previous studies have 252 
attributed albuminuria in animal models of ADPKD to disturbed endocytosis of albumin in 253 
the proximal tubule (24, 41). In these studies, immunohistochemistry showed less expression 254 
of the chloride channel ClC-5 and megalin, which are both involved in the reabsorption of 255 
low-molecular weight proteins. Because albumin, angiotensinogen, and renin are all 256 
reabsorbed by a megalin-dependent pathway, a proximal tubular disorder should by 257 
definition result in higher urinary angiotensinogen and renin excretion, even in the face of 258 
identical or lower plasma RAAS-component levels (28, 30). In agreement with this concept, 259 
we recently showed that patients with Dent’s disease (who lack ClC-5) displayed a 20-40-260 
fold rise in urinary angiotensinogen and renin levels, although their plasma RAAS levels 261 
were in the normal range (30). Similarly, other urinary markers of proximal tubule damage, 262 
such as fetuin-A and β2-microglobulin, are increased in ADPKD (22, 27). The ADPKD 263 
component that independently predicted urinary angiotensinogen and renin excretion in our 264 
multivariable regression analysis therefore possibly reflects a difference in tubular 265 
reabsorption. We showed that albuminuria correlated with total kidney volume (Figure 2A), 266 
as was shown previously (34). In addition to ADPKD, albuminuria also independently 267 
predicted urinary renin and angiotensinogen excretion. This also suggests that the urinary 268 





mechanisms, and argues against selective tubular secretion of RAAS-components. This 270 
leaves the issue of altered degradation. Reduced reabsorption would also be expected to 271 
result in elevated levels of RAAS-component degrading enzymes, leading to enhanced 272 
degradation. Yet, higher levels of urinary RAAS-components were found in ADPKD. 273 
Combined with data from previous studies showing no evidence for urinary degradation of 274 
renin or prorenin (38), and identifying all urinary angiotensinogen as intact (and not cleaved) 275 
(39), it appears that reduced degradation does not underlie the increased urinary excretion of 276 
angiotensinogen and renin in ADPKD.  277 
 278 
The possibility of ectopic RAAS-component production by cyst-lining epithelial cells has 279 
been suggested by several investigators (20, 35). Although we cannot entirely exclude this 280 
possibility, such local production should have resulted in angiotensinogen and renin 281 
concentrations in cyst fluid that would have been at least comparable to, if not far above, 282 
their plasma concentrations. Remarkably, this was not the case (Figure 3). In fact, relative to 283 
albumin, the concentrations of angiotensinogen, renin and prorenin were lower in cyst fluid 284 
(Figure 3). In other words, when using cyst albumin concentrations as a measure of blood-285 
derived proteins, cyst RAAS-component concentrations can be entirely explained on the 286 
basis of leakage from blood plasma. Of interest, the urinary concentrations of albumin, 287 
angiotensinogen, and prorenin were lower than their concentrations in cyst fluid. This most 288 
likely reflects further dilution and/or tubular reabsorption. Surprisingly, this was not the case 289 
for renin: its concentrations in cyst fluid and urine were similar (Figure 3). Moreover, the 290 
correlation between albumin and renin excretion, although modest, showed a different pattern 291 
in ADPKD than in CKD (Figure 2C). Taken together, these data suggest that ADPKD 292 
affects the urinary excretion of renin differently than of albumin, angiotensinogen and 293 





levels that are virtually undetectable), has been observed before (30, 38). Of note, we did not 295 
measure the sodium concentration in cyst fluid; previously, more active renin was found in 296 
so-called “gradient cysts” in which the sodium concentration is low (36).  297 
 298 
Many aspects of the intra-renal renin-angiotensin system remain unclear, although some 299 
groups have suggested that angiotensinogen and renin in tubular fluid may lead to high 300 
tubular angiotensin II levels (11, 20). Such high local angiotensin II levels could promote 301 
renal sodium retention, hypertension, kidney damage, or even cystogenesis (20). Of interest 302 
in this regard is a recent report where targeting the intra-renal renin-angiotensin system 303 
reduced cyst growth in an animal model of polycystic kidney disease (33). Based on our 304 
cross-sectional data, we cannot conclude whether the higher urinary angiotensinogen and 305 
renin excretions are a cause or a consequence of the kidney damage in ADPKD. In other 306 
words, it is unclear if higher urinary angiotensinogen and renin excretion should be 307 
considered as a damage marker or as a potential contributor to kidney damage. Given the 308 
experimental link between the intra-renal renin-angiotensin system and cystogenesis, this 309 
deserves further study.  310 
 311 
A number of limitations of this study should be mentioned. First, RAAS-inhibitor use could 312 
have influenced our results. Ideally, urinary RAAS-components should be measured before 313 
and after starting a RAAS-inhibitor. Previous studies have shown a decrease of urinary 314 
angiotensinogen and no effects on urinary renin after initiation of an angiotensin receptor 315 
blocker in patients with chronic kidney disease (26, 42). Therefore, if anything, our ADPKD 316 
group would be expected to have lower urinary angiotensinogen excretion, which was not the 317 
case. Second, despite matching of ADPKD with CKD patients by the most relevant 318 





difference in age was inevitable, as eGFR decline occurs much earlier in ADPKD than in 320 
other forms of CKD. We addressed these differences by using an adjusted analysis, 321 
multivariable analyses, and a subanalysis (Table 2, Table 3). Finally, although significant, 322 
the strength of the correlations observed in this study were modest, suggesting high inter-323 
individual variability or a multifactorial origin.  324 
 325 
In conclusion, ADPKD uniquely increases urinary angiotensinogen and renin excretion 326 
despite their circulating levels being comparable to those in CKD. We believe these findings 327 
warrant further analysis in mechanistic or intervention studies. 328 






The DIPAK Consortium is an inter-university collaboration in The Netherlands that is 331 
established to study ADPKD and to develop rational treatment strategies for this disease. 332 
Principal investigators are (in alphabetical order): J.P.H. Drenth (Department of 333 
Gastroenterology and Hepatology, Radboudumc Nijmegen), J.W. de Fijter (Department of 334 
Nephrology, Leiden University Medical Center [UMC]), R.T. Gansevoort (Department of 335 
Nephrology, UMC Groningen), M. Losekoot (Department of Human Genetics, Leiden 336 
UMC), E. Meijer (Department of Nephrology, UMC Groningen), D.J.M. Peters (Department 337 
of Human Genetics, Leiden UMC), F.W. Visser (Department of Nephrology, UMC 338 
Groningen), J.Wetzels (Department of Nephrology, Radboud UMC Nijmegen), and R. Zietse 339 
(Department of Internal Medicine, Erasmus MC Rotterdam). 340 
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Table 1: Comparison of studies measuring RAAS-components in patients with ADPKD 502 
 503 
Study Cases CKD stage Controls Numbers Measurement(s) Difference 
Valvo (37) ADPKD + HT 1-3 ADPKD + NT 20 vs. 12 PRA  
Bell (3) ADPKD + HT 1-2 ADPKD + NT 9 vs. 7 PRA during low/ high 
Na+ diet + ACEi 
 but  during 
ACEi + high Na+ 
diet 
Chapman (5) ADPKD  1 Essential HT + 
healthy controls 
14 + 11 vs. 
9 + 13 
PRA and aldo during 
ACEi 
PRA and aldo  in 
ADPKD + HT 
Harrap (13) ADPKD 1 Siblings 19 vs. 20 PRA and aldo PRA and aldo   
Watson (40) ADPKD  1-2 Siblings 13 vs. 10 PRA  
Barrett (1) ADPKD 1-2 Siblings 21 vs. 12 PRA and aldo during 
low/high Na+ diet, 




ADPKD + HT 2-3 Essential HT 20 vs. 20 PRA, aldosterone, ANP, 
Ang II 
 
Ramunni (29) ADPKD + HT 1-2 ADPKD + NT 17 vs. 17 PRA  
Doulton (7) ADPKD + HT 1-2 Essential HT 11 vs. 8 PRA during low/high 
Na+ diet and ACEi 
 
Kurultak (17) ADPKD 1 Healthy controls 20 vs. 20 Urinary AGT  
Kocyigit (15) ADPKD + HT 1-2 ADPKD + NT, 
healthy controls 
43 vs. 41 + 
40 
Plasma and urinary 
AGT 
Urinary AGT  
Park (25) ADPKD  1-5 None 186  Plasma renin+ aldo, 
urinary AGT 
Correlation urinary 
AGT with eGFR, 
TKV, BP 
Present study ADPKD 3 CKD 69 vs. 58 Plasma + urinary AGT, 
renin, aldo 
Urinary AGT + 
renin  
 504 
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ACEi, angiotensin 505 
converting enzyme inhibitor; AGT, angiotensinogen; aldo, aldosterone; Ang II, angiotensin 506 
II; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HT, 507 





Table 2: Patient characteristics and renin-angiotensin-aldosterone system measurements.  509 
Category Parameter ADPKD 
(n = 60) 
CKD  





Clinical data Age, years 47 ± 8 68 ± 8 < 0.001  
 Male gender, n (%) 25 (42) 25 (44) N.T.¶  
 Height, cm 175 ± 10 169 ± 9 0.001  
 Weight, kg 81.6 ± 17.0 81.2 ± 11.9 0.9  
 Hypertension, n (%)† 56 (93) 49 (86) N.T.  
 SBP, mmHg 131 ± 14 134 ± 14 N.T.  
 DBP, mmHg 79 ± 9 76 ± 7 N.T.  
 RAAS-inhibitors, n (%) 50 (83) 44 (77) N.T.  
 DDD RAAS-inhibitors, n 1.9 ± 1.5 1.1 ± 0.9 < 0.001  
Plasma  Creatinine, mg/dL 1.5 ± 0.4 1.4 ± 0.4 0.6  
 eGFR, ml/min per 1.73 m2 48 ± 11 46 ± 9 N.T.  
 Angiotensinogen, pmol/mL 1599 (313–8067) 1455 (474–3567) 0.3  
 Renin, pg/mL 81.3 (9.6–950.0) 68.3 (14.8–464.5) 0.3  
 Aldosterone, pg/mL 121.7 (16.5–470.1) 105.9 (16.6–546.4) 0.2  
Urine  Volume, mL/day 2233 (800–6500) 1652 (530–3140) < 0.001 0.2 
 Creatinine, mmol/day 13.3 (5.2–21.2) 10.9 (6.0–18.2) < 0.001 0.8 
 Albumin, mg/day 40.0 (3.1–266.4) 26.7 (3.4–293.2) 0.05 - 
 Sodium, mmol/day 150 (40 – 354) 142 (60 – 371) 0.5  
 Angiotensinogen, pmol/day 194.4 (3.5–3384.0) 36.0 (2.3–1070) < 0.001 < 0.001 
 Renin, pg/day 2717 (375.7–69248.0) 485.5 (154.7–2293.0) < 0.001 < 0.001 
 Aldosterone, µg/day 4.6 (0.9–32.8) 3.5 (1.0–18.0) 0.02 0.2 
Footnotes:  510 
*  Using analysis of variance (ANOVA) with log-transformed data as appropriate 511 
**  Using analysis of covariance (ANCOVA) with log-transformed data as appropriate 512 
and adjustments for age, height, defined daily dose, and albuminuria 513 






Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic 516 
kidney disease; DBP, diastolic blood pressure; DDD, defined daily dose; eGFR, estimated 517 






Table 3: Multivariable analysis of factors predicting urinary angiotensinogen and renin 520 
excretion. 521 
 522 
Variable Urinary angiotensinogen excretion Urinary renin excretion 
 β P-value β P-value 
Presence of ADPKD 9.6 (3.7 – 24.5) < 0.001 4.9 (2.6 – 9.0) < 0.001 
eGFR, ml/min/1.73 m2 0.96 (0.94 – 0.99) 0.002 0.99 (0.98 – 1.01) 0.3 
Age, years 1.0 (0.9 – 1.1) 0.2 0.99 (0.97 – 1.02) 0.6 
DDD RAAS-inhibitors, n 0.8 (0.7 – 1.0) 0.1 0.9 (0.8 – 1.1) 0.2 
Plasma renin, pg/mL 0.5 (0.3 – 1.0) 0.05 1.9 (1.2 – 2.9) 0.007 
Plasma AGT, pg/mL 3.0 (0.9 – 10.7) 0.08 1.1 (0.5 – 2.4) 0.9 
Urinary sodium, mmol/day 1.6 (0.4 – 7.1) 0.5 1.0 (0.4 – 2.8) 0.9 
Albuminuria, mg/day 6.2 (3.6 – 10.7) < 0.001 1.6 (1.1 – 2.3) 0.01 
 523 
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; AGT, 524 
angiotensinogen; DDD, defined daily dose; eGFR, estimated glomerular filtration rate; 525 
RAAS, renin-angiotensin-aldosterone system 526 





Legends to Figures 528 
 529 
Figure 1: Plasma concentrations and urinary excretions of angiotensinogen and renin in 530 
patients with ADPKD or CKD and with or without RAAS-inhibitors 531 
Box-and-whisker plots of plasma concentrations and urinary excretions of renin and 532 
angiotensinogen for ADPKD (light grey) and CKD (dark grey). Groups were subdivided into 533 
those with (+) and without (-) use of RAAS-inhibitors (RAASi). Of the 60 patients with 534 
ADPKD, 10 patients did not use RAASi; of the 57 CKD patients, 13 patients did not use 535 
RAASi. Boxes show the median, interquartile range and range. ANOVA was used for 536 
comparison with * P < 0.05. 537 
 538 
Figure 2: Correlations of RAAS-components with total kidney volume and kidney 539 
function 540 
Pearson correlation coefficients were calculated using log-transformed data. Height-adjusted 541 
total kidney volume was available in 51 patients with ADPKD. Correlations between urinary 542 
albumin, angiotensinogen, and renin excretion are shown both for patients with ADPKD and 543 
CKD.  544 
 545 
Figure 3: Concentrations of Albumin and RAAS-components in plasma, cyst fluid, and 546 
urine 547 
With plasma values set to 1, this figure shows the relative mean concentrations of albumin, 548 
angiotensinogen (AGT), prorenin, and renin in plasma (P), cyst fluid (C) and urine (U). The 549 
actual mean plasma concentrations were 42 g/L, 1814 pmol/L, 573.8 pg/mL, and 81.3 pg/mL, 550 
respectively. Measurements were performed in three ADPKD patients, who underwent 551 





with eGFRs of 12 and 9 mL/min/1.73 m
2
, respectively) or because of mechanical discomfort 553 
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